首页 > 最新文献

Cancer reports最新文献

英文 中文
TGFβ1 and SMAD3 Expression Are Associated With Survival After the Immune Checkpoint Inhibitor Therapy for Small Cell Lung Cancer tgf - β1和SMAD3表达与小细胞肺癌免疫检查点抑制剂治疗后的生存相关
IF 1.9 Q4 ONCOLOGY Pub Date : 2025-11-04 DOI: 10.1002/cnr2.70394
Zenta Seto, Minehiko Inomata, Akira Noguchi, Tomonobu Kado, Nozomu Murayama, Naoki Takata, Kotaro Tokui, Seisuke Okazawa, Shingo Imanishi, Tosihiro Miwa, Ryuji Hayashi, Kenichi Hirabayashi, Kazuyuki Tobe

Background

Tumor immunity is involved in the progression of malignant tumors. However, there are few reports on the relationship between the immunological environment and the efficacy of immune checkpoint inhibitors in small cell lung cancer (SCLC). We analyzed the relationship between tumor-infiltrating immune cells and protein expression and survival in patients with SCLC treated with combined therapy with immune checkpoint inhibitors plus chemotherapy.

Methods

Patients with SCLC who received combined therapy with immune checkpoint inhibitors plus chemotherapy between 2019 and 2023 were enrolled. Immune cell infiltration levels, including CD4, CD8, FOXP3, CD163-positive cells and expression levels of TGFβ1 and SMAD3 proteins in tumor tissue were evaluated by immunohistochemistry. Progression-free survival (PFS) and overall survival (OS) were evaluated as endpoints.

Results

Data from 22 patients were analyzed. The high CD4-positive T lymphocyte (p = 0.008, log-rank test) and the high CD8-positive T lymphocyte infiltration group (p = 0.031, log-rank test) showed statistically significantly longer OS than the low infiltration group. On the other hand, the low TGFβ1 expression group showed significantly longer PFS (p = 0.026, log-rank test) and the low SMAD3 expression group showed significantly longer OS (p = 0.042, log-rank test) than the high expression group.

Conclusion

In conclusion, it is suggested that infiltration of T lymphocytes and expression of TGFβ1 and SMAD3 may be related to the efficacy of the combined therapy with immune checkpoint inhibitors plus chemotherapy in patients with SCLC.

背景:肿瘤免疫参与恶性肿瘤的发展。然而,关于免疫检查点抑制剂在小细胞肺癌(SCLC)治疗中免疫环境与疗效之间关系的报道很少。我们分析了免疫检查点抑制剂加化疗联合治疗的SCLC患者肿瘤浸润免疫细胞与蛋白质表达和生存的关系。方法:纳入2019年至2023年期间接受免疫检查点抑制剂联合化疗的SCLC患者。免疫组化法检测肿瘤组织中CD4、CD8、FOXP3、cd163阳性细胞浸润水平及tgf - β1、SMAD3蛋白表达水平。无进展生存期(PFS)和总生存期(OS)作为终点进行评估。结果:分析了22例患者的资料。cd8高阳性T淋巴细胞组(p = 0.008, log-rank检验)和cd8高阳性T淋巴细胞浸润组(p = 0.031, log-rank检验)的OS均明显长于低浸润组。另一方面,tgf - β1低表达组的PFS显著长于高表达组(p = 0.026, log-rank检验),SMAD3低表达组的OS显著长于高表达组(p = 0.042, log-rank检验)。结论:综上所述,提示T淋巴细胞浸润及tgf - β1、SMAD3的表达可能与免疫检查点抑制剂联合化疗治疗SCLC患者的疗效有关。
{"title":"TGFβ1 and SMAD3 Expression Are Associated With Survival After the Immune Checkpoint Inhibitor Therapy for Small Cell Lung Cancer","authors":"Zenta Seto,&nbsp;Minehiko Inomata,&nbsp;Akira Noguchi,&nbsp;Tomonobu Kado,&nbsp;Nozomu Murayama,&nbsp;Naoki Takata,&nbsp;Kotaro Tokui,&nbsp;Seisuke Okazawa,&nbsp;Shingo Imanishi,&nbsp;Tosihiro Miwa,&nbsp;Ryuji Hayashi,&nbsp;Kenichi Hirabayashi,&nbsp;Kazuyuki Tobe","doi":"10.1002/cnr2.70394","DOIUrl":"10.1002/cnr2.70394","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Tumor immunity is involved in the progression of malignant tumors. However, there are few reports on the relationship between the immunological environment and the efficacy of immune checkpoint inhibitors in small cell lung cancer (SCLC). We analyzed the relationship between tumor-infiltrating immune cells and protein expression and survival in patients with SCLC treated with combined therapy with immune checkpoint inhibitors plus chemotherapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with SCLC who received combined therapy with immune checkpoint inhibitors plus chemotherapy between 2019 and 2023 were enrolled. Immune cell infiltration levels, including CD4, CD8, FOXP3, CD163-positive cells and expression levels of TGFβ1 and SMAD3 proteins in tumor tissue were evaluated by immunohistochemistry. Progression-free survival (PFS) and overall survival (OS) were evaluated as endpoints.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Data from 22 patients were analyzed. The high CD4-positive T lymphocyte (<i>p</i> = 0.008, log-rank test) and the high CD8-positive T lymphocyte infiltration group (<i>p</i> = 0.031, log-rank test) showed statistically significantly longer OS than the low infiltration group. On the other hand, the low TGFβ1 expression group showed significantly longer PFS (<i>p</i> = 0.026, log-rank test) and the low SMAD3 expression group showed significantly longer OS (<i>p</i> = 0.042, log-rank test) than the high expression group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In conclusion, it is suggested that infiltration of T lymphocytes and expression of TGFβ1 and SMAD3 may be related to the efficacy of the combined therapy with immune checkpoint inhibitors plus chemotherapy in patients with SCLC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 11","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12585284/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145444108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Internet-Based Interventions in Quality of Life Assessments Among Women Living With Breast Cancer: A Systematic and Meta-Analytic Approach 基于互联网的乳腺癌妇女生活质量评估干预:系统和荟萃分析方法
IF 1.9 Q4 ONCOLOGY Pub Date : 2025-10-31 DOI: 10.1002/cnr2.70358
Elsa Vitale, Kurvatteppa Halemani, Asha Shetty, Annarita Fanizzi, Samantha Bove, Maria Colomba Comes, Raffaella Massafra

Introduction

Internet-based interventions have become a necessity in providing care. To assess quality-of-life perceptions among women living with breast cancer (BC) receiving any type of internet-based treatments.

Methods

The present systematic review and meta-analysis were registered in PROSPERO with the ID no. CRD42024498834. All internet-based interventional studies among women living with BC assessing their quality of life perceptions before and after the intervention or between the usual and the intervention group were included. We consulted the British Nursing Database, CINHAL, Embase, Medline, Nursing & Allied Database, PubMed, Scopus, and Web of Science databases. Quality of life perceptions were assessed thanks to the Functional Assessment of Cancer Therapy–Breast (FACT-B) and the EORTC-QLQ-core Questionnaire (EORTC-QLQ-C30).

Results

The heterogeneity test findings of the eight studies exploring the FACT-B suggested that there was a significant heterogeneity among the selected studies (I2 = 68%, p = 0.002). The FACT-B mean score among women living with BC was 0.31 (95% CI: 0.08–0.53). The heterogeneity test among the four studies exploring the EORTC-QLQ-C30 score revealed that there was a significant heterogeneity among the selected studies (I2 = 74%, p = 0.009). The EORTC-QLQ-C30 mean score was 0.24 (95% CI: −0.11 to 0.58).

Conclusion

Internet-based interventions could ameliorate quality of life perceptions since most of the enrolled participants revealed as complicated the home community management allowing regular participation.

基于互联网的干预措施已成为提供护理的必要条件。评估接受网络治疗的乳腺癌(BC)女性患者的生活质量。方法本系统评价和荟萃分析在PROSPERO注册,ID号为。CRD42024498834。所有在BC患者中进行的基于互联网的干预研究,评估了她们在干预前后或在常规组和干预组之间的生活质量感知。我们查阅了英国护理数据库、CINHAL、Embase、Medline、护理联合数据库、PubMed、Scopus和Web of Science数据库。通过乳腺癌治疗功能评估(FACT-B)和eortc - qlq核心问卷(EORTC-QLQ-C30)评估生活质量感知。结果8项探讨FACT-B的研究的异质性检验结果表明,所选研究之间存在显著的异质性(I2 = 68%, p = 0.002)。BC患者的FACT-B平均评分为0.31 (95% CI: 0.08-0.53)。四项EORTC-QLQ-C30评分研究的异质性检验显示,所选研究之间存在显著的异质性(I2 = 74%, p = 0.009)。EORTC-QLQ-C30平均评分为0.24 (95% CI: - 0.11 ~ 0.58)。结论基于网络的干预可以改善生活质量感知,因为大多数参与者反映家庭社区管理复杂,允许定期参与。
{"title":"Internet-Based Interventions in Quality of Life Assessments Among Women Living With Breast Cancer: A Systematic and Meta-Analytic Approach","authors":"Elsa Vitale,&nbsp;Kurvatteppa Halemani,&nbsp;Asha Shetty,&nbsp;Annarita Fanizzi,&nbsp;Samantha Bove,&nbsp;Maria Colomba Comes,&nbsp;Raffaella Massafra","doi":"10.1002/cnr2.70358","DOIUrl":"https://doi.org/10.1002/cnr2.70358","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Internet-based interventions have become a necessity in providing care. To assess quality-of-life perceptions among women living with breast cancer (BC) receiving any type of internet-based treatments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The present systematic review and meta-analysis were registered in PROSPERO with the ID no. CRD42024498834. All internet-based interventional studies among women living with BC assessing their quality of life perceptions before and after the intervention or between the usual and the intervention group were included. We consulted the British Nursing Database, CINHAL, Embase, Medline, Nursing &amp; Allied Database, PubMed, Scopus, and Web of Science databases. Quality of life perceptions were assessed thanks to the Functional Assessment of Cancer Therapy–Breast (FACT-B) and the EORTC-QLQ-core Questionnaire (EORTC-QLQ-C30).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The heterogeneity test findings of the eight studies exploring the FACT-B suggested that there was a significant heterogeneity among the selected studies (<i>I</i><sup>2</sup> = 68%, <i>p</i> = 0.002). The FACT-B mean score among women living with BC was 0.31 (95% CI: 0.08–0.53). The heterogeneity test among the four studies exploring the EORTC-QLQ-C30 score revealed that there was a significant heterogeneity among the selected studies (<i>I</i><sup>2</sup> = 74%, <i>p</i> = 0.009). The EORTC-QLQ-C30 mean score was 0.24 (95% CI: −0.11 to 0.58).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Internet-based interventions could ameliorate quality of life perceptions since most of the enrolled participants revealed as complicated the home community management allowing regular participation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 11","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70358","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145407226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mouse Models of Osteosarcoma: Unraveling Disease Mechanisms and Accelerating Drug Discovery and Development 骨肉瘤的小鼠模型:揭示疾病机制和加速药物发现和开发
IF 1.9 Q4 ONCOLOGY Pub Date : 2025-10-31 DOI: 10.1002/cnr2.70390
Staci L. Haney, Sarah A. Holstein

Background

Osteosarcoma is the most frequent primary bone malignancy, affecting mainly children, adolescents, and young adults. For the past 40 years, improvements in the survival of patients with osteosarcoma have been minimal, primarily as a consequence of the lack of systemic therapy options beyond traditional cytotoxic agents. In particular, management of metastatic and recurrent disease continues to be a significant clinical challenge.

Recent Findings

Mouse models of osteosarcoma serve as a valuable tool to study disease biology, metastasis, and response to novel treatments. In recent years, mouse models have been employed to evaluate the efficacy of several innovative drugs, including nanoparticle formulations that can target drug delivery to osteosarcoma tumor cells and diminish off-target effects. In addition, significant preclinical advancements in immune checkpoint inhibitors and immunotherapies for osteosarcoma have been made with the aid of mouse models.

Conclusion

This review provides insight into the advantages and shortcomings of the numerous osteosarcoma mouse models described in the literature, including transgenic, orthotopic, and heterotopic models as well as patient-derived xenografts. We highlight how these models are currently being used to support preclinical studies focused on the development of novel therapies.

骨肉瘤是最常见的原发性骨恶性肿瘤,主要影响儿童、青少年和年轻人。在过去的40年里,骨肉瘤患者生存率的改善一直很小,主要是因为除了传统的细胞毒性药物之外缺乏全身治疗选择。特别是,转移性和复发性疾病的管理仍然是一个重大的临床挑战。骨肉瘤的小鼠模型是研究疾病生物学、转移和对新疗法反应的有价值的工具。近年来,小鼠模型被用来评估几种创新药物的疗效,包括纳米颗粒制剂,它可以靶向给药到骨肉瘤肿瘤细胞并减少脱靶效应。此外,在小鼠模型的帮助下,免疫检查点抑制剂和骨肉瘤免疫疗法的临床前研究取得了重大进展。本文综述了文献中描述的多种骨肉瘤小鼠模型的优点和缺点,包括转基因、原位、异位模型以及患者来源的异种移植。我们强调了这些模型目前如何被用于支持临床前研究,重点是开发新的治疗方法。
{"title":"Mouse Models of Osteosarcoma: Unraveling Disease Mechanisms and Accelerating Drug Discovery and Development","authors":"Staci L. Haney,&nbsp;Sarah A. Holstein","doi":"10.1002/cnr2.70390","DOIUrl":"https://doi.org/10.1002/cnr2.70390","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Osteosarcoma is the most frequent primary bone malignancy, affecting mainly children, adolescents, and young adults. For the past 40 years, improvements in the survival of patients with osteosarcoma have been minimal, primarily as a consequence of the lack of systemic therapy options beyond traditional cytotoxic agents. In particular, management of metastatic and recurrent disease continues to be a significant clinical challenge.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Recent Findings</h3>\u0000 \u0000 <p>Mouse models of osteosarcoma serve as a valuable tool to study disease biology, metastasis, and response to novel treatments. In recent years, mouse models have been employed to evaluate the efficacy of several innovative drugs, including nanoparticle formulations that can target drug delivery to osteosarcoma tumor cells and diminish off-target effects. In addition, significant preclinical advancements in immune checkpoint inhibitors and immunotherapies for osteosarcoma have been made with the aid of mouse models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This review provides insight into the advantages and shortcomings of the numerous osteosarcoma mouse models described in the literature, including transgenic, orthotopic, and heterotopic models as well as patient-derived xenografts. We highlight how these models are currently being used to support preclinical studies focused on the development of novel therapies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 11","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70390","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145407225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acceptance in Patients With Cancer: A Scoping Review 癌症患者的接受度:一项范围综述。
IF 1.9 Q4 ONCOLOGY Pub Date : 2025-10-30 DOI: 10.1002/cnr2.70324
Joost Dekker, Chris Welling, Mariette Labots

Background

Cancer is generally perceived as a major stressor. Occasionally, patients are able to accept their diagnosis and prognosis, and it is not uncommon for patients who initially experience great distress to eventually learn to accept their disease. A deeper understanding of acceptance can enable clinicians to better support patients in achieving a more peaceful state of mind. The purpose of this literature review was to provide a comprehensive overview of existing research on acceptance in patients with cancer.

Recent Findings

Study selection resulted in the inclusion of 54 studies. All studies except one were published after the year 2000. Acceptance was defined in terms of cognition, emotion, behavior, spiritual processes, social processes, or other terms. Acceptance focused on disease, illness, cancer, poor prognosis/imminent death, or was not specified, and was measured by interview or questionnaire. Evidence was found for a range of factors associated with acceptance.

Conclusions

Acceptance is a relatively new field of research, characterized by significant heterogeneity in both its definition and focus, as well as the hypothesized determinants and outcomes. To advance this field, it is essential to develop a generally accepted definition of acceptance and to consistently specify its focus. The present scoping review provides a solid foundation for this endeavor.

背景:癌症通常被认为是一个主要的压力源。偶尔,患者能够接受他们的诊断和预后,并且对于最初经历巨大痛苦的患者最终学会接受他们的疾病并不罕见。对接受的更深入的理解可以使临床医生更好地支持患者实现更平静的心态。本文献综述的目的是对现有的癌症患者接受性研究提供一个全面的概述。最近的发现:研究选择结果包括54项研究。除了一项研究外,所有的研究都是在2000年之后发表的。接受被定义为认知、情感、行为、精神过程、社会过程或其他术语。接受度集中在疾病、疾病、癌症、预后不良/即将死亡或未指定,并通过访谈或问卷调查进行测量。研究发现了一系列与接受度相关的因素。结论:接受是一个相对较新的研究领域,其特点是其定义和重点,以及假设的决定因素和结果都具有显著的异质性。为了推动这一领域的发展,必须制定一个普遍接受的接受定义,并始终如一地指定其重点。目前的范围审查为这一努力提供了坚实的基础。
{"title":"Acceptance in Patients With Cancer: A Scoping Review","authors":"Joost Dekker,&nbsp;Chris Welling,&nbsp;Mariette Labots","doi":"10.1002/cnr2.70324","DOIUrl":"10.1002/cnr2.70324","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cancer is generally perceived as a major stressor. Occasionally, patients are able to accept their diagnosis and prognosis, and it is not uncommon for patients who initially experience great distress to eventually learn to accept their disease. A deeper understanding of acceptance can enable clinicians to better support patients in achieving a more peaceful state of mind. The purpose of this literature review was to provide a comprehensive overview of existing research on acceptance in patients with cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Recent Findings</h3>\u0000 \u0000 <p>Study selection resulted in the inclusion of 54 studies. All studies except one were published after the year 2000. Acceptance was defined in terms of cognition, emotion, behavior, spiritual processes, social processes, or other terms. Acceptance focused on disease, illness, cancer, poor prognosis/imminent death, or was not specified, and was measured by interview or questionnaire. Evidence was found for a range of factors associated with acceptance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Acceptance is a relatively new field of research, characterized by significant heterogeneity in both its definition and focus, as well as the hypothesized determinants and outcomes. To advance this field, it is essential to develop a generally accepted definition of acceptance and to consistently specify its focus. The present scoping review provides a solid foundation for this endeavor.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 11","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70324","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145400058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intradural Extramedullary Spinal Cord Metastasis of Breast Cancer in a Male: A Case Report 男性乳腺癌硬膜内髓外脊髓转移1例。
IF 1.9 Q4 ONCOLOGY Pub Date : 2025-10-29 DOI: 10.1002/cnr2.70382
Hadi Mohammed Abdullah, Naa Adzoa Adzeley Boi-Dsane, George Wepeba, Thomas Dakurah

Introduction

Breast cancer in males is rare, accounting for just 0.5% to 1% according to World Health Organization data. This is the first reported case of IESCM from breast cancer in an African male, which makes it noteworthy. Furthermore, unlike previously reported cases in females, this case involved L1–L2 metastasis with sphincter dysfunction and a subsequent relapse leading to mortality, thereby expanding the documented spectrum of IESCM presentations and outcomes.

Case Presentation

This is a case of a 77-year-old male with invasive ductal carcinoma of the left breast and intradural extramedullary spinal cord metastasis diagnosed via Magnetic Resonance Imaging after presenting with neurological symptoms 4 years post-mastectomy. He eventually passed away following a right Deep Venous Thrombosis, which led to bilateral pulmonary embolism after his second relapse.

Conclusion

Late presentation most likely contributed to the worsening of symptoms and poor prognosis. This report overstates the importance of prompt access to healthcare and the essence of thorough investigations, especially in breast cancer, where neurological symptoms may point to a metastatic diagnosis.

导读:根据世界卫生组织的数据,男性乳腺癌很少见,仅占0.5%至1%。这是非洲男性乳腺癌引起IESCM的首例报道,值得注意。此外,与先前报道的女性病例不同,该病例涉及L1-L2转移伴括约肌功能障碍,随后复发导致死亡,从而扩大了IESCM的表现和结果。病例介绍:这是一个77岁男性左乳浸润性导管癌及硬膜内髓外脊髓转移的病例,在乳房切除术后4年出现神经系统症状,经磁共振诊断。他最终在右深静脉血栓形成后去世,在他第二次复发后导致双侧肺栓塞。结论:迟发是导致症状加重和预后不良的主要原因。该报告夸大了及时获得医疗保健的重要性和彻底调查的本质,特别是在乳腺癌中,神经系统症状可能指向转移诊断。
{"title":"Intradural Extramedullary Spinal Cord Metastasis of Breast Cancer in a Male: A Case Report","authors":"Hadi Mohammed Abdullah,&nbsp;Naa Adzoa Adzeley Boi-Dsane,&nbsp;George Wepeba,&nbsp;Thomas Dakurah","doi":"10.1002/cnr2.70382","DOIUrl":"10.1002/cnr2.70382","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Breast cancer in males is rare, accounting for just 0.5% to 1% according to World Health Organization data. This is the first reported case of IESCM from breast cancer in an African male, which makes it noteworthy. Furthermore, unlike previously reported cases in females, this case involved L1–L2 metastasis with sphincter dysfunction and a subsequent relapse leading to mortality, thereby expanding the documented spectrum of IESCM presentations and outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>This is a case of a 77-year-old male with invasive ductal carcinoma of the left breast and intradural extramedullary spinal cord metastasis diagnosed via Magnetic Resonance Imaging after presenting with neurological symptoms 4 years post-mastectomy. He eventually passed away following a right Deep Venous Thrombosis, which led to bilateral pulmonary embolism after his second relapse.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Late presentation most likely contributed to the worsening of symptoms and poor prognosis. This report overstates the importance of prompt access to healthcare and the essence of thorough investigations, especially in breast cancer, where neurological symptoms may point to a metastatic diagnosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 11","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70382","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145399611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cuproptosis-Related Ferroptosis Gene Signature: A Prognostic Tool for Colon Cancer Patients 铜垂相关的铁下垂基因标记:结肠癌患者的预后工具
IF 1.9 Q4 ONCOLOGY Pub Date : 2025-10-28 DOI: 10.1002/cnr2.70372
Yanlin Tan, Jinxiu Zhang, Ruoxi Cheng, Wenfang Yang, Xiaoping Pan, Kaoyan Feng, Mengbin Qin, Jie'an Huang

Background

Ferroptosis and cuprotosis, two distinct mechanisms of programmed cell death, play key roles in colon cancer development. This study aimed to construct a prognostic model for predicting colon adenocarcinoma (COAD) prognosis based on the differential expression of cuproptosis-related ferroptosis genes (CFRGs).

Methods and Results

Transcriptomic data and clinical data of COAD patients were obtained from The Cancer Genome Atlas and Gene Expression Omnibus databases. A combination of methods, including analysis of variance, Pearson correlation analysis, Least absolute shrinkage and selection operator (LASSO) algorithm, and Cox regression was used to construct the CFRGs signatures. In addition, multiple algorithmic strategies were employed to explore the potential association between risk scores and immune infiltration features. Single-cell datasets were used to analyze model genes. Somatic mutations and drug sensitivities were compared across risk groups. Immunohistochemical analysis was performed to verify the expression of the main characterized genes. We identified eight pivotal genes in constructing the CFRGs signature. Single-cell RNA sequencing revealed differential expression of CFRGs in the COAD tumor microenvironment. The nomogram confirmed that risk scoring serves as an independent prognostic factor for COAD. The high-risk group exhibited higher immune cell and stromal cell infiltration, as well as immune checkpoint expression. Patients in the high-risk group may benefit from olanzapine administration. Both RT-PCR and immunohistochemistry have confirmed that the expression levels of GLS and YAP1 in COAD tissues are significantly higher than those in adjacent non-cancerous tissues.

Conclusions

The CFRGs risk prognosis model can effectively predict patients' immune infiltration and immunotherapy response, providing a new reference basis for individualized treatment plans for COAD patients.

背景:铁下垂和铜坏死是两种不同的程序性细胞死亡机制,在结肠癌的发展中起着关键作用。本研究旨在构建基于cuprotosis相关铁下垂基因(CFRGs)差异表达的预测结肠癌(COAD)预后的预后模型。方法与结果从Cancer Genome Atlas和Gene Expression Omnibus数据库中获取COAD患者的转录组学数据和临床资料。综合运用方差分析、Pearson相关分析、LASSO算法和Cox回归等方法构建CFRGs特征。此外,采用多种算法策略来探索风险评分与免疫浸润特征之间的潜在关联。单细胞数据集用于分析模型基因。对不同风险组的体细胞突变和药物敏感性进行比较。免疫组化分析证实了主要特征基因的表达。我们确定了构建CFRGs特征的8个关键基因。单细胞RNA测序显示CFRGs在COAD肿瘤微环境中的差异表达。nomogram证实了风险评分作为COAD的独立预后因素。高危组免疫细胞和基质细胞浸润增多,免疫检查点表达增多。高危组患者可从奥氮平治疗中获益。RT-PCR和免疫组化均证实,GLS和YAP1在COAD组织中的表达水平明显高于癌旁非癌组织。结论CFRGs风险预后模型可有效预测患者免疫浸润及免疫治疗反应,为COAD患者的个体化治疗方案提供新的参考依据。
{"title":"Cuproptosis-Related Ferroptosis Gene Signature: A Prognostic Tool for Colon Cancer Patients","authors":"Yanlin Tan,&nbsp;Jinxiu Zhang,&nbsp;Ruoxi Cheng,&nbsp;Wenfang Yang,&nbsp;Xiaoping Pan,&nbsp;Kaoyan Feng,&nbsp;Mengbin Qin,&nbsp;Jie'an Huang","doi":"10.1002/cnr2.70372","DOIUrl":"https://doi.org/10.1002/cnr2.70372","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Ferroptosis and cuprotosis, two distinct mechanisms of programmed cell death, play key roles in colon cancer development. This study aimed to construct a prognostic model for predicting colon adenocarcinoma (COAD) prognosis based on the differential expression of cuproptosis-related ferroptosis genes (CFRGs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Transcriptomic data and clinical data of COAD patients were obtained from The Cancer Genome Atlas and Gene Expression Omnibus databases. A combination of methods, including analysis of variance, Pearson correlation analysis, Least absolute shrinkage and selection operator (LASSO) algorithm, and Cox regression was used to construct the CFRGs signatures. In addition, multiple algorithmic strategies were employed to explore the potential association between risk scores and immune infiltration features. Single-cell datasets were used to analyze model genes. Somatic mutations and drug sensitivities were compared across risk groups. Immunohistochemical analysis was performed to verify the expression of the main characterized genes. We identified eight pivotal genes in constructing the CFRGs signature. Single-cell RNA sequencing revealed differential expression of CFRGs in the COAD tumor microenvironment. The nomogram confirmed that risk scoring serves as an independent prognostic factor for COAD. The high-risk group exhibited higher immune cell and stromal cell infiltration, as well as immune checkpoint expression. Patients in the high-risk group may benefit from olanzapine administration. Both RT-PCR and immunohistochemistry have confirmed that the expression levels of GLS and YAP1 in COAD tissues are significantly higher than those in adjacent non-cancerous tissues.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The CFRGs risk prognosis model can effectively predict patients' immune infiltration and immunotherapy response, providing a new reference basis for individualized treatment plans for COAD patients.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 11","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70372","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145375339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinicopathological Diagnosis and Prognosis of Endometrioid Borderline Ovarian Tumors: Dual Case Reports and Literature Review 子宫内膜样交界性卵巢肿瘤的临床病理诊断及预后:两例报告及文献复习
IF 1.9 Q4 ONCOLOGY Pub Date : 2025-10-28 DOI: 10.1002/cnr2.70388
Fang Yang, Dong Chen, Qian Sun, Jingjing Yu, Xue Wang

Introduction

Endometrioid borderline ovarian tumor (EBOT) is rare and frequently misdiagnosed. This study aims to investigate the clinicopathological features, immunohistochemical characteristics, differential diagnosis, therapeutic approaches and disease prognosis, thereby establishing a robust foundation to mitigate misdiagnosis risks and deepen insights into the pathological diagnosis of this disease.

Case Presentations

From May 2020 to December 2022, two female patients diagnosed with EBOT were enrolled at Ningbo Yinzhou No. 2 Hospital. The patients, aged 30 and 34 years, respectively, both underwent left adnexal resection. Microscopically, the tumors displayed disorganized crowded endometrioid glands, mild-to-moderate epithelial atypia, and fibrous stroma interspersed among glands. Mulberry-like squamous metaplasia was also observed in some areas. Tumor cells were positive for cytokeratin (CK), cytokeratin 7 (CK7), estrogen receptor (ER) and progesterone receptor (PR), but negative for Wilms' tumor 1 (WT-1). The Ki-67 index ranged from 3% to 10%. Genetic analysis revealed a heterozygous CTNNB1 deletion in one tumor, whereas a heterozygous PTEN deletion in the other. As of the current follow-up (ranging from 10 to 40 months), both cases remained in a tumor-free status, with no signs of recurrence or metastasis to date.

Conclusion

EBOT are infrequent and may coexist with endometriosis or endometrioid carcinoma. Our cases demonstrated a heterozygous deletion of the CTNNB1 gene in one case, while a heterozygous deletion of the PTEN gene in the other. Surgery remains the main treatment, reflecting its efficacy in achieving disease control and a favorable prognosis.

子宫内膜样交界性卵巢肿瘤(EBOT)是一种罕见且常被误诊的肿瘤。本研究旨在探讨本病的临床病理特征、免疫组织化学特征、鉴别诊断、治疗方法和疾病预后,为降低误诊风险和加深对本病病理诊断的认识奠定坚实的基础。2020年5月至2022年12月,宁波市鄞州第二医院招募了2例确诊为EBOT的女性患者。患者年龄分别为30岁和34岁,均行左附件切除术。显微镜下,肿瘤显示杂乱拥挤的子宫内膜样腺,轻度至中度上皮异型性,纤维间质散布于腺体之间。部分地区可见桑葚样鳞状化生。肿瘤细胞中细胞角蛋白(CK)、细胞角蛋白7 (CK7)、雌激素受体(ER)和孕激素受体(PR)均呈阳性,Wilms' Tumor 1 (WT-1)呈阴性。Ki-67指数为3% ~ 10%。遗传分析显示,在一个肿瘤中存在CTNNB1杂合缺失,而在另一个肿瘤中存在PTEN杂合缺失。截至目前的随访(10至40个月),两例患者均处于无肿瘤状态,未出现复发或转移迹象。结论EBOT少见,可能与子宫内膜异位症或子宫内膜样癌共存。我们的病例显示了CTNNB1基因的杂合缺失,而PTEN基因的杂合缺失在另一个病例中。手术仍然是主要的治疗方法,反映了其在实现疾病控制和良好预后方面的有效性。
{"title":"Clinicopathological Diagnosis and Prognosis of Endometrioid Borderline Ovarian Tumors: Dual Case Reports and Literature Review","authors":"Fang Yang,&nbsp;Dong Chen,&nbsp;Qian Sun,&nbsp;Jingjing Yu,&nbsp;Xue Wang","doi":"10.1002/cnr2.70388","DOIUrl":"https://doi.org/10.1002/cnr2.70388","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Endometrioid borderline ovarian tumor (EBOT) is rare and frequently misdiagnosed. This study aims to investigate the clinicopathological features, immunohistochemical characteristics, differential diagnosis, therapeutic approaches and disease prognosis, thereby establishing a robust foundation to mitigate misdiagnosis risks and deepen insights into the pathological diagnosis of this disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentations</h3>\u0000 \u0000 <p>From May 2020 to December 2022, two female patients diagnosed with EBOT were enrolled at Ningbo Yinzhou No. 2 Hospital. The patients, aged 30 and 34 years, respectively, both underwent left adnexal resection. Microscopically, the tumors displayed disorganized crowded endometrioid glands, mild-to-moderate epithelial atypia, and fibrous stroma interspersed among glands. Mulberry-like squamous metaplasia was also observed in some areas. Tumor cells were positive for cytokeratin (CK), cytokeratin 7 (CK7), estrogen receptor (ER) and progesterone receptor (PR), but negative for Wilms' tumor 1 (WT-1). The Ki-67 index ranged from 3% to 10%. Genetic analysis revealed a heterozygous <i>CTNNB1</i> deletion in one tumor, whereas a heterozygous <i>PTEN</i> deletion in the other. As of the current follow-up (ranging from 10 to 40 months), both cases remained in a tumor-free status, with no signs of recurrence or metastasis to date.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>EBOT are infrequent and may coexist with endometriosis or endometrioid carcinoma. Our cases demonstrated a heterozygous deletion of the <i>CTNNB1</i> gene in one case, while a heterozygous deletion of the <i>PTEN</i> gene in the other. Surgery remains the main treatment, reflecting its efficacy in achieving disease control and a favorable prognosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 11","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70388","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145375338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Pediatric Case of Hepatocellular Malignant Neoplasm, Not Otherwise Specified (HCN-NOS) With Poor Prognosis Post-Tumor Resection and Postoperative Chemotherapy 小儿无特异性肝细胞恶性肿瘤(HCN-NOS) 1例,肿瘤切除及术后化疗后预后不良。
IF 1.9 Q4 ONCOLOGY Pub Date : 2025-10-23 DOI: 10.1002/cnr2.70378
Bin Yamaoka, Reina Hoshi, Kako Ono, Takayuki Hirano, Yosuke Watanabe, Shumpei Goto, Takashi Hosokawa, Shuichiro Uehara

Introduction

Hepatocellular malignant neoplasm, not otherwise specified (HCN-NOS) is a newly identified liver tumor with features of mixed hepatoblastoma (HB) and hepatocellular carcinoma (HCC). Although its prognosis and treatment strategies are not well defined, some reports suggested that complete resection with HB-targeting chemotherapy may yield favorable outcomes.

Case Presentation

We present herein a pediatric case of HCN-NOS in which the tumor was fully resected followed by postoperative chemotherapy. Unfortunately, the patient subsequently died.

Conclusion

This case highlights the fact that hepatoblastoma protocols may not always be effective in the treatment of HCN-NOS; therefore, developing treatment strategies tailored to HCN-NOS is crucial to improve patient prognosis.

简介:肝细胞恶性肿瘤(Hepatocellular malignant neoplasm, not other specified, HCN-NOS)是一种新发现的肝脏肿瘤,具有肝母细胞瘤(HB)和肝细胞癌(HCC)的混合特征。虽然其预后和治疗策略尚不明确,但一些报道表明,完全切除hb靶向化疗可能会产生良好的结果。病例介绍:我们在此报告一个小儿HCN-NOS病例,其中肿瘤被完全切除,术后化疗。不幸的是,病人随后死亡。结论:本病例强调肝母细胞瘤治疗方案可能并不总是有效的;因此,制定针对HCN-NOS的治疗策略对于改善患者预后至关重要。
{"title":"A Pediatric Case of Hepatocellular Malignant Neoplasm, Not Otherwise Specified (HCN-NOS) With Poor Prognosis Post-Tumor Resection and Postoperative Chemotherapy","authors":"Bin Yamaoka,&nbsp;Reina Hoshi,&nbsp;Kako Ono,&nbsp;Takayuki Hirano,&nbsp;Yosuke Watanabe,&nbsp;Shumpei Goto,&nbsp;Takashi Hosokawa,&nbsp;Shuichiro Uehara","doi":"10.1002/cnr2.70378","DOIUrl":"10.1002/cnr2.70378","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Hepatocellular malignant neoplasm, not otherwise specified (HCN-NOS) is a newly identified liver tumor with features of mixed hepatoblastoma (HB) and hepatocellular carcinoma (HCC). Although its prognosis and treatment strategies are not well defined, some reports suggested that complete resection with HB-targeting chemotherapy may yield favorable outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>We present herein a pediatric case of HCN-NOS in which the tumor was fully resected followed by postoperative chemotherapy. Unfortunately, the patient subsequently died.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case highlights the fact that hepatoblastoma protocols may not always be effective in the treatment of HCN-NOS; therefore, developing treatment strategies tailored to HCN-NOS is crucial to improve patient prognosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70378","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145353949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stress and Support Present in Medical Crowdfunding in Pediatric Cancer 儿童癌症医疗众筹中的压力与支持
IF 1.9 Q4 ONCOLOGY Pub Date : 2025-10-19 DOI: 10.1002/cnr2.70375
Mary K. Killela, Sandra Garcia, Jessica Keim-Malpass, Sandra Soto, Todd Schwartz, Jessica Williams, Sheila Santacroce

Background

Medical crowdfunding (MCF) seeks to mitigate the financial harm to families with a child with cancer.

Aims

We sought to describe the illness phases, campaign creators, and the main topics discussed on MCF pages.

Methods and Results

Using publicly available campaigns on GoFundMe.com, we randomly selected 100 campaigns to extract information on stressors, appraisals, and additional attributes. We conducted descriptive statistics to describe the distributions of illness phases, creators, and topics, and Fisher's exact test to explore patterns in topics by illness phase and topics by creators.

Primary therapy was the most common illness phase (75%), and friend or family of the child with cancer was the most common campaign creator (76%). In 30/76 friend or family creators, a parent posted updates. The most common financial stressors were deductibles/co-pay costs (60%), employment disruptions (58%), and treatment-related travel (47%). Nearly all campaigns mentioned non-financial stressors including describing the illness (88%) and the path to diagnosis (86%). Most campaigns included a tertiary appraisal of worthiness to explain why their child (75%) or the family (49%) was worthy of donations. Most campaigns provided emotional support (84%), few provided peer support (22%), and even fewer provided informational support (10%). There were many significant differences in topics by type of creator and few by illness phase.

Conclusions

Friends and family are most active in creating campaigns near the beginning of a child's cancer journey. Campaigners share information both to update and to convince donors to support them. Future work should explore the consequences of parents engaging in MCF.

医疗众筹(MCF)旨在减轻有癌症儿童的家庭的经济损失。我们试图描述疾病阶段、活动发起人和MCF页面上讨论的主要主题。方法和结果使用GoFundMe.com上公开的活动,我们随机选择了100个活动来提取有关压力源、评估和其他属性的信息。我们进行了描述性统计来描述疾病阶段、创造者和主题的分布,并使用Fisher的精确检验来探索疾病阶段和创造者主题之间的模式。初级治疗是最常见的疾病阶段(75%),癌症儿童的朋友或家人是最常见的活动发起人(76%)。在30/76的朋友或家庭创作者中,父母发布了更新。最常见的财务压力因素是免赔额/自付费用(60%)、就业中断(58%)和治疗相关的旅行(47%)。几乎所有的运动都提到了非经济压力因素,包括描述疾病(88%)和诊断途径(86%)。大多数活动都包括对价值的第三级评估,以解释为什么他们的孩子(75%)或家庭(49%)值得捐赠。大多数活动提供情感支持(84%),很少提供同伴支持(22%),提供信息支持的更少(10%)。不同类型的创造者在主题上有很多显著的差异,而疾病阶段的差异很少。在儿童癌症之旅开始时,朋友和家人最积极地发起活动。活动人士分享信息是为了更新和说服捐助者支持他们。未来的工作应该探索父母参与MCF的后果。
{"title":"Stress and Support Present in Medical Crowdfunding in Pediatric Cancer","authors":"Mary K. Killela,&nbsp;Sandra Garcia,&nbsp;Jessica Keim-Malpass,&nbsp;Sandra Soto,&nbsp;Todd Schwartz,&nbsp;Jessica Williams,&nbsp;Sheila Santacroce","doi":"10.1002/cnr2.70375","DOIUrl":"https://doi.org/10.1002/cnr2.70375","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Medical crowdfunding (MCF) seeks to mitigate the financial harm to families with a child with cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>We sought to describe the illness phases, campaign creators, and the main topics discussed on MCF pages.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>Using publicly available campaigns on GoFundMe.com, we randomly selected 100 campaigns to extract information on stressors, appraisals, and additional attributes. We conducted descriptive statistics to describe the distributions of illness phases, creators, and topics, and Fisher's exact test to explore patterns in topics by illness phase and topics by creators.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <p>Primary therapy was the most common illness phase (75%), and friend or family of the child with cancer was the most common campaign creator (76%). In 30/76 friend or family creators, a parent posted updates. The most common financial stressors were deductibles/co-pay costs (60%), employment disruptions (58%), and treatment-related travel (47%). Nearly all campaigns mentioned non-financial stressors including describing the illness (88%) and the path to diagnosis (86%). Most campaigns included a tertiary appraisal of worthiness to explain why their child (75%) or the family (49%) was worthy of donations. Most campaigns provided emotional support (84%), few provided peer support (22%), and even fewer provided informational support (10%). There were many significant differences in topics by type of creator and few by illness phase.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Friends and family are most active in creating campaigns near the beginning of a child's cancer journey. Campaigners share information both to update and to convince donors to support them. Future work should explore the consequences of parents engaging in MCF.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70375","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145317391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inflammatory Markers in Combination With Multiple Patterns of Extrarenal Extension Accurately Indicate Recurrence Risk in Patients With pT3aN0M0 Clear Cell Renal Cell Carcinoma 炎症标志物联合多种肾外延伸模式准确指示pT3aN0M0透明细胞肾癌患者复发风险
IF 1.9 Q4 ONCOLOGY Pub Date : 2025-10-18 DOI: 10.1002/cnr2.70371
Masato Uetani, Fumito Yamabe, Shunsuke Hori, Mizuki Kasahara, Mizuho Okawa, Hideyuki Kobayashi, Koichi Nagao, Koichi Nakajima, Yozo Mitsui

Background and Aims

A clear understanding of the risk of clear cell renal cell carcinoma (ccRCC) recurrence in individual patients is essential for appropriate administration of adjuvant therapy. Notably, non-metastatic pT3a ccRCCs are heterogeneous, and affected patients will have a different prognosis depending on the pathological definition. The present study was conducted to identify factors associated with postoperative recurrence in pT3a ccRCC cases.

Methods

We retrospectively reviewed 295 patients who underwent a radical or partial nephrectomy for RCC at our institution from 2013 to 2022 and identified 42 with pT3aN0M0 ccRCC. Preoperative clinical and pathological data, including blood parameters, were collected, and their association with recurrence-free survival (RFS) was evaluated. The Kaplan–Meier method and uni- and multivariable Cox proportional hazard regression were used for statistical analysis.

Results

Univariate and subsequent multivariate analyses showed white blood cells, platelets, and mixed patterns of pT3a components as independent prognostic factors with significant relationships with RFS. Kaplan–Meier curves revealed that the presence of leukocytosis or thrombocytosis was associated with worse RFS (p = 0.0002, p < 0.0001, respectively), while patients with a mixed pattern of pT3a components also had worse RFS as compared to those with a single pattern (p = 0.0007). Furthermore, accuracy for prediction of RFS in pT3a ccRCC cases was improved by classification based on the number of retained factors, that is, leukocytosis, thrombocytosis, and mixed patterns of pT3a components.

Conclusions

The present findings indicate that inflammatory markers, such as leukocytes and platelets, as well as multiple patterns of extrarenal extension are factors useful for predicting RFS in patients with pT3aN0M0 ccRCC. Their combined use should aid in the selection of appropriate postoperative adjuvant therapy.

背景和目的:清楚地了解单个透明细胞肾细胞癌(ccRCC)复发的风险对于适当给予辅助治疗至关重要。值得注意的是,非转移性pT3a ccrcc是异质的,受影响的患者会根据病理定义有不同的预后。本研究旨在确定pT3a ccRCC患者术后复发的相关因素。方法:我们回顾性分析了2013年至2022年在我院接受肾细胞癌根治性或部分切除的295例患者,其中42例为pT3aN0M0型肾细胞癌。收集术前临床和病理资料,包括血液参数,并评估其与无复发生存期(RFS)的关系。采用Kaplan-Meier法、单变量和多变量Cox比例风险回归进行统计分析。结果:单因素和随后的多因素分析显示,白细胞、血小板和pT3a成分的混合模式是与RFS有显著关系的独立预后因素。Kaplan-Meier曲线显示,白细胞增多或血小板增多与较差的RFS相关(p = 0.0002, p)。结论:目前的研究结果表明,炎症标志物,如白细胞和血小板,以及多种肾外延伸模式是预测pT3aN0M0 ccRCC患者RFS的有用因素。它们的联合使用应有助于选择适当的术后辅助治疗。
{"title":"Inflammatory Markers in Combination With Multiple Patterns of Extrarenal Extension Accurately Indicate Recurrence Risk in Patients With pT3aN0M0 Clear Cell Renal Cell Carcinoma","authors":"Masato Uetani,&nbsp;Fumito Yamabe,&nbsp;Shunsuke Hori,&nbsp;Mizuki Kasahara,&nbsp;Mizuho Okawa,&nbsp;Hideyuki Kobayashi,&nbsp;Koichi Nagao,&nbsp;Koichi Nakajima,&nbsp;Yozo Mitsui","doi":"10.1002/cnr2.70371","DOIUrl":"10.1002/cnr2.70371","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>A clear understanding of the risk of clear cell renal cell carcinoma (ccRCC) recurrence in individual patients is essential for appropriate administration of adjuvant therapy. Notably, non-metastatic pT3a ccRCCs are heterogeneous, and affected patients will have a different prognosis depending on the pathological definition. The present study was conducted to identify factors associated with postoperative recurrence in pT3a ccRCC cases.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively reviewed 295 patients who underwent a radical or partial nephrectomy for RCC at our institution from 2013 to 2022 and identified 42 with pT3aN0M0 ccRCC. Preoperative clinical and pathological data, including blood parameters, were collected, and their association with recurrence-free survival (RFS) was evaluated. The Kaplan–Meier method and uni- and multivariable Cox proportional hazard regression were used for statistical analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Univariate and subsequent multivariate analyses showed white blood cells, platelets, and mixed patterns of pT3a components as independent prognostic factors with significant relationships with RFS. Kaplan–Meier curves revealed that the presence of leukocytosis or thrombocytosis was associated with worse RFS (<i>p</i> = 0.0002, <i>p</i> &lt; 0.0001, respectively), while patients with a mixed pattern of pT3a components also had worse RFS as compared to those with a single pattern (<i>p</i> = 0.0007). Furthermore, accuracy for prediction of RFS in pT3a ccRCC cases was improved by classification based on the number of retained factors, that is, leukocytosis, thrombocytosis, and mixed patterns of pT3a components.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The present findings indicate that inflammatory markers, such as leukocytes and platelets, as well as multiple patterns of extrarenal extension are factors useful for predicting RFS in patients with pT3aN0M0 ccRCC. Their combined use should aid in the selection of appropriate postoperative adjuvant therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 10","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70371","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145312490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1